Association Between FDA Buprenorphine Labeling Change to Improve Access and Medicare Part D Prior Authorization Requirement

This study describes changes in the proportion of Medicare Part D plans requiring prior authorization for buprenorphine products before and after a 2017 FDA rquirement that the drug ’s label emphasize the importance of drug treatment of opioid use disorder.
Source: JAMA - Category: General Medicine Source Type: research